What Viramal does

Viramal is a UK-based specialty pharmaceutical company founded in April 2013 by Oliver Bates and Dr. Finn Larsen, with a wholly-owned subsidiary in Sweden supporting development operations. The company is focused exclusively on women's sexual and reproductive health therapeutics, targeting conditions including endometriosis, Female Androgen Deficiency Syndrome (FADS), chronic period pain, menopause, vaginal atrophy, and fertility challenges that the company describes as poorly served by existing drugs.

The company develops its products on a proprietary drug delivery platform called Fem Med Tech, which uses patented skin reservoir technology and a unique vaginal delivery platform to deliver active pharmaceutical ingredients transdermally or vaginally through cream formulations. The pipeline includes VML-0501 (a trans-vaginally delivered endometriosis candidate positioned as the first product to reach the pelvic cavity and preserve fertility), the ELEGANT (TM) portfolio of seven OTC female sexual health products planned for first US launch, menopausal hormone therapy creams, female and male testosterone replacement therapies, vaginal microbiome products, and earlier-stage programmes in vaginal cannabinoids and transdermal iron supplementation.

Viramal's intended revenue model is dual-track: prescription pharmaceutical products distributed through healthcare providers (targeting enterprise/clinical channels globally) and over-the-counter products sold directly to consumers, with the ELEGANT portfolio as the first OTC launch in the United States. Pricing has not been publicly disclosed and the company has not reported commercial revenue; its only disclosed financial relationship is a board observer seat held by METIS Family Office A/S / Investeringsselskabet MFO Private Equity A/S, with the DPTI Fund also holding a board seat. The company employs 11-50 staff and is privately held.

Name

Viramal

Legal name

Viramal Limited

Website

https://viramal.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Viramal is a UK-based specialty pharmaceutical company developing women's health therapeutics via its proprietary Fem Med Tech transdermal/vaginal cream platform, with a pipeline spanning endometriosis (VML-0501), OTC sexual health (ELEGANT), menopausal hormone therapy, and testosterone replacement products.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Women’s Health (OTC Gynecologic) (HLAIADAJ), Menstrual Pain Relief & Period Care Supplements (CRABAIAJ), Fertility & Ovulation Products (OTC) (CRABAIAK)

Keywords

• Women's health therapeutics
• Transdermal drug delivery
• Endometriosis treatment
• Hormone replacement therapy
• Vaginal health products

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Prescription Pharmaceutical Products: Prescription treatments developed for endometriosis, menopausal hormone therapy, and other women's health conditions. Products are in various stages of clinical development including VML-0501 for endometriosis.
2. Over-the-Counter (OTC) Products: The ELEGANT (TM) Portfolio will be Viramal's first OTC product launching in the United States, targeting female sexual health and vaginal microbiome balance.
3. Transdermal Hormone Therapies: Low-dose female hormone therapies delivered transdermally for systemic benefit and vaginally for localised symptoms, expected to demonstrate improved bioavailability.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Viramal is a specialty pharmaceutical company that develops prescription and over-the-counter treatments for women's sexual and reproductive health conditions, including endometriosis, menopause, female sexual health, fertility, and vaginal microbiome disorders. Products are formulated using the proprietary Fem Med Tech platform, which delivers active pharmaceutical ingredients through transdermal and vaginal cream formulations designed to increase potency, enable targeted tissue delivery, and minimise systemic side effects. The portfolio spans both clinical-stage prescription drug candidates and OTC consumer products such as the ELEGANT (TM) line.

Product overview

Viramal is a specialist UK-based pharmaceutical company with a subsidiary in Sweden developing a portfolio of transformative healthcare products for women. The company's Fem Med Tech platform powers multiple product candidates spanning both prescription and over-the-counter treatments: VML-0501 for endometriosis (in clinical trials), the ELEGANT (TM) over-the-counter vaginal health portfolio including an Elegant Vaginal Moisturiser (registration in process), menopausal hormone therapy creams, female and male testosterone replacement therapies, vaginal microbiome products for conception preparation, and earlier-stage programmes in vaginal cannabinoids and iron supplementation. Products are delivered via proprietary transdermal or vaginal cream formulations.

Differentiator

Problem solved

Functional benefit

Brands

• ELEGANT (TM) Portfolio: A pioneering range of female sexual health products including vaginal moisturiser targeting vaginal infection and microbiome balance; the first OTC product planned for US launch.
• Fem Med Tech™

Products and services

• VML-0501 Trans-vaginally delivered prescription drug candidate for endometriosis, positioned as the first treatment to preserve hormone balance and fertility ability, target pelvic cavity tissue via vaginal administration, rejuvenate ovarian tissue, and improve the telomere pathway in women with poor reproductive outcomes.
• ELEGANT (TM) Portfolio Pioneering OTC product range of seven female sexual health products, including an Elegant Vaginal Moisturiser that treats vaginal atrophy through microbiome balancing; aimed at alleviating vaginal discharge, tackling vaginal infection without antibiotics via anti-adhesion strategies, and promoting optimal vaginal health. First OTC product planned for US launch.
• Menopausal Hormone Therapy Products Range of low-dose female hormone therapies for hormone replacement treatment, delivered transdermally for systemic benefit and vaginally for localised symptoms. Formulated as an easy-to-use cosmetic-grade cream for daily use supporting healthier ageing.
• Female Testosterone Replacement Therapy Patented female testosterone product delivered as a regular daily dose to combat Female Androgen Deficiency Syndrome (FADS), characterised by fatigue, disturbed sleep, low energy, motivation and self-esteem, and lack of sexual libido. Positioned as the first registered female testosterone product.
• Male Testosterone Replacement Therapy Patient-acceptable transdermal testosterone cream suitable for use in chronic conditions, designed to contribute to the male hormone therapy market.
• Vaginal Microbiome Products Products that help create and maintain a healthy vaginal environment by supporting a pH-balanced microbiome essential for a woman's sexual and reproductive lifecycle, particularly targeted at women preparing to conceive and maintain healthy pregnancies.
• Vaginal Cannabinoids Research-stage therapies for chronic pelvic inflammatory diseases leveraging the high density of cannabinoid receptors in female pelvic organs, indicating strong propensity for cannabis absorption, treatment and efficacy.
• Iron Supplementation Transdermal or buccal iron therapies for Iron Deficiency Anemia (IDA), offering easy iron absorption and avoidance of gastrointestinal issues that plague existing oral iron supplementation.

Quantifiable outcome

• First treatment to preserve hormone balance and the ability to conceive for endometriosis patients
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• BigelcoreOthersViramal acquired Bigel, an established company, to develop their pioneering product portfolio of women's health therapies.

Recent moves7 records

Expansion highlights6 records

Direct peers

• Theramex: Specialty pharmaceutical company exclusively dedicated to women's health, with portfolio spanning menopause, contraception, and reproductive medicine. Closely comparable as a women's health-only specialty pharma with similar therapeutic focus areas to Viramal's pipeline.
• Evofem Biosciences: Women's health commercial-stage biopharmaceutical company with Phexxi vaginal gel for contraception and ongoing development in sexual health. Comparable focus on vaginal delivery formats and women's sexual/reproductive health commercialization.
• TherapeuticsMD: Specialty pharmaceutical company focused exclusively on women's health, with marketed products in menopause hormone therapy and vaginal health. Direct overlap with Viramal's prescription and OTC women's health strategy, including similar focus on differentiated hormone delivery and vaginal health.
• Myovant Sciences: Women's health pharma company developing therapies for uterine fibroids, endometriosis, and advanced prostate cancer. Directly comparable as a women's health-focused development-stage pharma with competing endometriosis asset (relugolix combination therapy), and was acquired by Sumitomo Pharma.
• Daré Bioscience: Clinical-stage biopharmaceutical company focused on women's health with pipeline in contraception, vaginal health, and menopause. Comparable in stage and therapeutic focus, though Daré emphasizes contraceptive innovation and vaginal ring delivery rather than transdermal creams.
• Agile Therapeutics: Women's health pharmaceutical company with FDA-approved Twirla contraceptive patch and pipeline in additional women's health indications. Comparable as a small-cap women's health pharma developing differentiated delivery formats for reproductive-age women.

Emerging players

• ObsEva: Clinical-stage biopharmaceutical company developing therapies for women's reproductive health, with lead asset in preterm labor and pipeline in endometriosis. Comparable as a small women's health-focused development company, though currently facing significant financial distress.

Broad incumbents

• Bayer (Women's Health): Global pharma with substantial women's health franchise including Mirena IUD, Yaz/Yasmin oral contraceptives, and hormone therapy products. Major incumbent with overlapping menopause, contraception, and reproductive health offerings and significant commercial scale.
• Organon & Co. Global women's health-focused pharmaceutical company spun off from Merck in 2021, with established portfolio in contraception, fertility, menopause, and biosimilars. Broad incumbent with overlapping therapeutic areas including hormone therapy and reproductive health, serving as both competitor and potential acquirer.
• AbbVie: Global pharmaceutical leader with major women's health franchise including Orilissa/Oriahnn for endometriosis and Lupron for reproductive conditions. Major incumbent competitor whose commercial infrastructure and payer relationships set the bar Viramal must clear to capture endometriosis market share.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/viramal-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viramal